Telisotuzumab-EMRELIS is developed and produced by which company and drug qualification description

Telisotuzumab Vedotin‑tllv (trade name: Emrelis) is developed and produced by AbbVie Inc., a world-renowned biopharmaceutical company. The drug is an innovative antibody-drug conjugate (ADC), which combines a monoclonal antibody targeting the c‑MET receptor with a cytotoxic loadmonomethyl auristatin E (MMAE) is combined to achieve precise killing of tumor cells while minimizing damage to normal tissues.

In terms of drug indications, Emrelis is mainly used for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC), which requires high expression of tumor cellsc‑MET protein (≥50%strong staining of tumor cells3+), and the patient has received systemic treatment. The drug received accelerated approval from the US FDA in May 2025, marking its breakthrough in the field of precision targeted tumor treatment.

AbbVieAs a R&D and manufacturer, it has complete drug development and commercialization experience in the field of oncology. The launch of Emrelis demonstrates the company’s continued investment and innovation capabilities in the direction of precision treatment of solid tumors. Currently, the drug is still exclusively available overseas as the original drug, and there is no publicly available generic version.

Overall,Telisotuzumab Vedotin‑tllv (Emrelis) has clear drug qualifications, reliable R&D background, and is a targetc‑Antibody-drug conjugates of MET receptors have important clinical value in certain NSCLC patients. Although it has not yet been launched in China, as the drug approval process progresses, it is expected to provide new treatment options for eligible domestic patients in the future.

Reference materials:https://www.drugs.com/